
Objectives Maternal separation (MS) stress consider as a risk factor for the development of autistic-like phenotype. Neuroinflammation is involved in the pathophysiology of autism. Neuroprotective effects have been shown for folic acid. The effects of folic acid on autistic-like phenotype in MS mice, focusing its probable effects on gene expression of Hmgb1, Nlrp3 and mTOR in the hippocampus evaluated. Methods MS mice orally received normal saline (10 mL/kg) or folic acid at doses of 5, 10, and 20 mg/kg for 14 days. Three-chamber sociability, shuttle box, and marble burying tests (MBT) were performed. Hippocampal expression of Hmgb1, Nlrp3 and mTOR genes was measured. Results Folic acid increased the sociability index (SI) and social preference index (SPI) in the three-chamber test (p < 0.001 for all doses), increased step-through latency in the shuttle box test (p < 0.01 for dose of 20 mg/kg) and reduced repetitive behaviours in the MBT (p < 0.05, p < 0.01 and p < 0.001 for doses of 5, 10 and 20 mg/kg, respectively). Folic acid decreased the gene expression of Hmgb1, Nlrp3 and mTOR (p < 0.001 for all doses). Conclusions Folic acid alleviated autistic-like behaviours in MS mice, probably through decrease in Hmgb1, Nlrp3 and mTOR mRNA gene expressions in the hippocampus.
OBJECTIVES:Schizophrenia is known to be accompanied by chronic sterile inflammation and elevated circulating cell-free DNA (cfDNA) levels, but the cellular sources have not been fully identified. The aim of this study was to test the hypothesis regarding the contribution of NETosis to the increase in cfDNA and to investigate associations between cfDNA and DNA-associated molecules levels with clinical features and antipsychotic dosage in schizophrenia. METHODS:This case-control study included 63 healthy subjects and 60 patients with schizophrenia. Concentrations in plasma of total, nuclear, and mitochondrial cfDNA, total histone H3, and anti-DNA antibodies as non-specific markers of cell stress/death, and also high-mobility group protein B1 (HMGB1) and citrullinated histone H3 (CitH3) as NETosis-related biomarkers, were analysed using fluorimetric analysis, digital PCR, and ELISA. RESULTS:Total cfDNA levels increased concomitantly with increases in nuclear cfDNA, histone H3, and anti-DNA antibodies, indicating a nuclear origin of plasma cfDNA, while mitochondrial cfDNA decreased in schizophrenia. Correlation analysis revealed a decrease in mitochondrial cfDNA with increasing antipsychotic therapy dosage. NETosis-related markers, CitH3 and HMGB1, did not changed significantly. CONCLUSIONS:These findings did not provide direct evidence linking active NETosis to elevated cfDNA levels, suggesting the involvement of other cell death processes; however, they highlighted the associations between cfDNA and clinical features in schizophrenia.
OBJECTIVE:Ketamine is a rapid-acting antidepressant with an incompletely understood mechanism of action. Pharmacometabolomics can identify pathways underlying its effects and response variability. Using data from the Bio-K trial (NCT03156504), a multisite open-label study, we characterised metabolomic signatures of intravenous (IV) racemic ketamine in adults with treatment-resistant depression (TRD). METHODS:Sixty-nine adults with TRD and major depressive disorder received three ketamine infusions (0.5 mg/kg). Remission was defined as MADRS ≤9 at 24 h post-third infusion. Metabolomic profiling used the Biocrates MxP® Q500 kit (>600 metabolites). Mixed-effects models assessed changes across time points (pre-dose, post-infusion 1, post-infusion 3), adjusting for age, sex, infusion length (first), and body mass index, with false discovery rate correction. RESULTS:Mean MADRS improved from 27.8 ± 5.8 to 11.1 ± 9.1 post-third infusion (p < 0.001); 54% achieved remission. Post-infusion 1, ketamine was associated with increased acylcarnitines, cortisol, amino acids (glutamine, glycine, BCAAs), and biogenic amines (GABA, putrescine), with reduced medium-chain acylcarnitines and glutamate. Post-infusion 3, C16, serotonin, and GABA elevations persisted while cortisol normalised. Remitters showed greater GABA synthesis increases, however, no metabolite change correlated with MADRS improvement after correction for multiple testing. CONCLUSIONS:Ketamine exposure was correlated with broad metabolic alterations spanning mitochondrial activation, neurotransmitter modulation, and neuroendocrine signalling. These findings represent metabolic correlates of ketamine exposure and remission, rather than validated predictors or established mechanistic drivers of antidepressant response. TRIAL REGISTRATION:ClinicalTrials.gov: NCT03156504.
OBJECTIVES:Depression involves interacting immune, oxidative, metabolic, neuroendocrine and neuroplasticity networks. This review evaluates mechanistic, preclinical, human and translational evidence for resveratrol in depression. METHODS:We conducted a structured narrative review of English-language literature to 30 June 2026 using PubMed, Web of Science Core Collection, Scopus and ScienceDirect, supplemented by Google Scholar and citation searching. After duplicate removal, 4,461 records were screened, 142 full texts assessed and 71 publications included. RESULTS:Antidepressant-like effects were reported across stress, endocrine, developmental, post-stroke, metabolic and gut-inflammatory models, involving SIRT1/AMPK, NF-κB/ NLRP3, Nrf2/HO-1, mitochondrial and ferroptosis pathways,monoaminergic and cAMP/PKA/CREB/BDNF signalling, and gut brain communication. However, many studies used preventive or concurrent dosing, male animals, high doses or non-oral routes. Human studies were few, heterogeneous and mainly non psychiatric, and do not establish efficacy for major depressive disorder. Nanoformulations may improve exposure, but depression specific clinical validation is lacking. CONCLUSIONS:Current evidence does not support resveratrol as monotherapy or an established depression treatment. It is better positioned as a mechanistic probe and hypothesis-generating adjunctive candidate. Future studies should prioritise therapeutic designs, pharmacokinetic monitoring, standardised outcomes and adequately powered adjunctive trials.